Intellia Therapeutics walks into its Q1 2026 earnings report — due after the close on May 14 — carrying the heaviest short positioning it has seen in weeks and a Street that is rapidly repricing what this gene-editing story is worth.
Short interest has climbed sharply. At 37.4% of the free float, it is the highest reading in over a month and up 15.7% on the week alone. The move is almost entirely a this-week story: shorts added roughly 5.7 million shares in just two sessions on May 11 and 12, lifting the total from around 37.6 million shares to 43.3 million. Days-to-cover of 4.3 days means unwinding that position is not a trivial exercise. Borrow costs, while still cheap in absolute terms at 0.75%, have jumped 32% in a week — a sign that demand for the short has risen faster than available supply can absorb it. Availability has tightened as a result, though it remains within a range that does not yet constitute a hard squeeze.
Options positioning tells a markedly different story. The put/call ratio is running at 0.31, almost exactly in line with its 20-day average, with a z-score essentially flat at zero. For a stock with more than one-third of its float sold short, the absence of elevated put demand is notable. It suggests that whatever conviction the shorts carry, options traders are not rushing to hedge or pile on ahead of the print — the options market looks almost indifferent.
The analyst tape has been active but divided. Bernstein raised its target to $17 this morning while holding a Market Perform, and Wedbush reiterated Neutral at $12 — both firmly in the cautious camp. HC Wainwright and Canaccord both kept Buy ratings but cut their targets to $25 and $49 respectively, the latter a trim from $58 just two weeks after raising it. Goldman Sachs, which carries a Sell, lifted its target modestly to $9. The mean analyst target has landed at $27.68 against a closing price of $13.99 — a gap so wide that it reflects the extreme dispersion of views rather than consensus confidence. Bulls point to the Phase 3 HAELO data showing 97% of patients attack-free after receiving lonvo-z, the Regeneron and Novartis collaborations, and a cash runway now extended into late 2027. Bears flag the financing overhang, commercial execution risk at launch, and competitive pressure in HAE. ORTEX factor scores underscore the difficulty of the bull case: the short score ranks in the 6th percentile of the universe, meaning it sits among the most heavily short-positioned stocks in the market, while EPS momentum over both 30 and 90 days is deeply negative, ranking at the 11th and 22nd percentiles respectively.
Institutional ownership adds an interesting dimension. ARK Investment Management is the largest holder at 10.2% of shares, having added 2.3 million shares as recently as April 30. Vanguard and BlackRock are the next largest, each adding meaningful positions in the most recent filing period. Strategic holder Regeneron — itself a collaboration partner — maintains a 2.65% stake unchanged. That combination of active-manager buying alongside significant short positioning sets up a clear tug-of-war heading into the print.
The May 14 earnings release is the event that will resolve much of this tension. At $13.99, the stock has recovered 5% on the week after a rough month, but the short rebuild of the past two sessions shows bears are unwilling to cover ahead of the release. The next session will reveal whether the HAELO momentum — and any update on the lonvo-z commercial path — is enough to give ARK and the buy-side bulls any ammunition.
See the live data behind this article on ORTEX.
Open NTLA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
